Market introduction of a remote and price efficient tool the screening of jaundice.

The need: Worldwide, 114.000 newborns die each year due to neonatal jaundice, a common condition caused by elevated levels of bilirubin. Current solutions for jaundice diagnosis require hospital laboratory facilities for blood testing and newborn monitoring by professional healthcare workers. Estimations indicate that jaundice management increases healthcare costs €1.684 million every year. Additionally, in low income countries (where most of the fatalities and brain damage occur) cannot afford blood tests and longer hospital stays to detect and treat jaundice properly. Our Solution: Picterus is an innovative Smartphone-based system that monitors jaundice in newborns. We provide healthcare workers and parents of newborns an easy-to-use, price-efficient App that screens for jaundice with 76% accuracy and 95.2% sensibility, without the need to visit hospitals. Our unique technology detects bilirubin levels by taking babies´ skin pictures, automatically interpreting the results and enabling nurses, midwives and parents to follow the next steps. Market opportunity: The mHealth market is rapidly growing and it is expected to reach 58.8 billion U.S. dollars by 2020. Of the 135 million newborns in the world each year, 81 to 108 million will suffer from jaundice. Picterus can be included in the routine newborn tests at hospitals worldwide and can also be used by parents and midwives at home to monitor the baby, thus reducing newborn deaths by 114.000 worldwide every year. We estimate a reduction of €842 million every year in healthcare system costs thanks to our solution. Company Impact: Picterus will be launch to the market by 2021 after full development of our technology, automatization of the colour calibration card production and successful completion of clinical trials in order to obtain CE marking approval as Class IIa medical device. We envision that after three years of commercialization (by 2023), we will reach €9.6M in revenue and achieve €14,1M by 2025.